Abstract
5-Lipoxygenase, which leads to the biosynthesis of proinflammatory lipid mediators, is involved in the pathogenesis of cancer. Experimental studies have demonstrated that 5-lipoxygenase inhibitors have antitumoral properties. Here, we describe the compelling evidence that 5-lipoxygenase inhibition is a rational therapy for certain cancers and for adjuvant approaches to cancer therapy.
Keywords: 5-lipoxygenase, Eicosanoids, Cancer therapy, Lipoxygenase inhibitors
Article Metrics
2